Please login to the form below

Not currently logged in
Email:
Password:

Boehringer’s head of pharma heads for the exit

Comes amid restructuring and bolt-on deals to bolster business

BI

German drugmaker Boehringer Ingelheim is making changes at the top following the news that head of pharma Allan Hillgrove is retiring.

Hillgrove - a 37-year veteran at Boehringer - will step down by the end of the year and will be replaced by Carine Brouillon, who joined the company from Johnson & Johnson last year and is currently its head of prescription medicines.

Hillgrove

Allan Hillgrove

Company chairman Christian Boehringer said Hillgrove had made a significant contribution to the launch of new drugs like Ofev (nintedanib) for pulmonary fibrosis and diabetes therapy Jardiance (empagliflozin) and “thus the sustainable development of the company”.

Jardiance and Ofev are currently driving growth at the drugmaker, contributing almost €1.7bn to pharma revenues of €6.8bn in the first half of the year, and the company has also been particularly active of late in expanding it pipeline with bolt-on deals as it works through a business restructuring.

cb

Carine Bruillon

Recent deals have included a €325m acquisition of AMAL Therapeutics to gain access to its cancer vaccine technology, a $226m alliance with UK-listed biotech PureTech Health to develop a new approach to cancer immunotherapy, a €1.1bn licensing deal for an Ofev follow-up from Bridge Biotherapeutics, and an $870m tie-up with Yuhan for a non-alcoholic steatohepatitis (NASH) drug.

Brouillon will officially take over on 1 January 2020, taking over the responsibility of bedding in those new collaborations and spearheading new launches such as Ofev for systemic sclerosis.

The reshuffle is extending into other business units as well, with Joachim Hasenmaier - board member with responsibility for both animal and consumer health - stepping down after 18 years with the company.

Hasenmaier will also retire by the end of the year and will be succeeded as head of animal health by Jean Scheftsik de Szolnok, currently Boehringer’s animal health managing director in France.

28th August 2019

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...
APAC map
Pharmaceutical innovation in the APAC region
A first-of-its-kind study paints a vivid picture of the APAC region’s future...

Infographics